Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

In-gel digestion for mass spectrometric characterization of proteins and proteomes

Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,947

Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips

Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089

Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells

Ahmed, E. N., Cutmore, L. C., & Marshall, J. F. (2024) · Cancers · doi:10.3390/cancers16183186 · Cited by 32

Advances in Chimeric Antigen Receptor T‐Cell Therapies for Solid Tumors

Baybutt, T. R., Flickinger, J. C., Caparosa, E. M., & Snook, A. E. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1280 · Cited by 28

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29

Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment

Li, X., Chen, T., Li, X., Zhang, H., Li, Y., Zhang, S., Luo, S., & Zheng, T. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00564-w · Cited by 28

Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling

Andreou, T., Neophytou, C., Kalli, M., Mpekris, F., & Stylianopoulos, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638186 · Cited by 27

Paving New Roads for CARs

Wittsten, A. H., & Roybal, K. T. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.005 · Cited by 27

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins

Blaeschke, F., Stenger, D., Apfelbeck, A., Cadilha, B. L., Benmebarek, M.-R., Mahdawi, J., Ortner, E., Lepenies, M., Habjan, N., Rataj, F., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00499-z · Cited by 27

Sweet Immune Checkpoint Targets to Enhance T Cell Therapy

Derosiers, N., Aguilar, W., Degaramo, D. A., & Posey, A. D. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100706 · Cited by 27

Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy

Balagopal, S., Sasaki, K., Kaur, P., Nikolaidi, M., & Ishihara, J. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00592a · Cited by 27

Cellular vesicles expressing PD-1-blocking scFv reinvigorate T cell immunity against cancer

Xue, T., Zhang, Z., Fang, T., Li, B., Li, Y., Li, L., Jiang, Y.-H., Duan, F., Meng, F., Liang, X., et al. (2022) · Nano Research · doi:10.1007/s12274-022-4182-0 · Cited by 27

Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy

Xia, W., Chen, J., Hou, W., Chen, J., Xiong, Y., Li, H., Qi, X., Xu, H. Y., Xie, Z., Li, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076843 · Cited by 27

T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer

Eisenberg, V., Hoogi, S., Shamul, A., Barliya, T., & Cohen, C. J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.007 · Cited by 27

Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

Yang, P., Wang, Y., Yao, Z., Gao, X., Liu, C., Wang, X., Wu, H., Xu, D., Hu, J., Lin, B., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c08538 · Cited by 27

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy

Zhang, Y., Wang, P., Wang, T., Fang, Y., Ding, Y., & Qian, Q. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02750-4 · Cited by 26

HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo

Jiang, Z., Liang, H., Pan, H., Yue, L., Wang, H., Yang, X., Lu, P., Zhang, X., Yang, J., Zhang, D., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.684016 · Cited by 26

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Chung, H., Jung, H., & Noh, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212126 · Cited by 28

Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future

Kringel, R., Lamszus, K., & Mohme, M. (2023) · Cells · doi:10.3390/cells12131770 · Cited by 26

Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors

Abken, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.165 · Cited by 27

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

Arunachalam, A. K., Grégoire, C., de Oliveira, B. C., & Melenhorst, J. J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101241 · Cited by 27

Chimeric antigen receptor T-cell therapy for melanoma

Razavi, A., Keshavarz-Fathi, M., Pawelek, J., & Rezaei, N. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1880895 · Cited by 25

Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Eeckhout, B. V. D., Huyghe, L., Lint, S. V., Burg, E., Plaisance, S., Peelman, F., Cauwels, A., Uzé, G., Kley, N., Gerlo, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003293 · Cited by 25

Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners

Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25

Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy

Jiang, Y., Wen, W., Yang, F., Han, D., Zhang, W., & Qin, W. (2022) · Cancers · doi:10.3390/cancers14040967 · Cited by 26

Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis

Jiang, G., Ng, Y. Y., Tay, J. C.-K., Du, Z., Xiao, L., Wang, S., & Zhu, J. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03247-9 · Cited by 25

Mapping CAR T-Cell Design Space Using Agent-Based Models

Prybutok, A. N., Yu, J. S., Leonard, J. N., & Bagheri, N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.849363 · Cited by 28

Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness

Lau, E. K., Kwong, G., Fowler, T. W., Sun, B.-C., Donohoue, P. D., Davis, R. T., Bryan, M. B., McCawley, S., Clarke, S., Williams, C., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.03.011 · Cited by 25

CAR-T cell therapy: a game-changer in cancer treatment and beyond

Utkarsh, K., Srivastava, N., Kumar, S., Khan, A. U., Dagar, G., Kumar, M., Singh, M. K., & Haque, S. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03368-2 · Cited by 28

Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model

Wang, Y., Cho, J.-W., Kastrunes, G. M., Buck, A., Razimbaud, C., Culhane, A. C., Sun, J., Braun, D. A., Choueiri, T. K., Wu, C. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108879 · Cited by 25

Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies

Olejarz, W., Sadowski, K. A., Szulczyk, D., & Basak, G. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147743 · Cited by 26

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies

Blanco, B., Ramírez-Fernández, Á., & Álvarez‐Vallina, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01792 · Cited by 25

Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy

Zhu, Q., Yu, C., Chen, Y., Luo, W., Li, M., Zou, J., Xiao, F., An, S., Saiding, Q., Tao, W., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2418306122 · Cited by 26

Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art

Abramson, J. S., Lunning, M. A., & Palomba, M. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238693 · Cited by 24

In Vivo Activation of Pro-Protein Therapeutics via Chemically Engineered Enzyme Cascade Reaction

Yang, X., Chang, J., Jiang, Y. Y., Xu, Q., Wang, M., & Mao, L. (2020) · CCS Chemistry · doi:10.31635/ccschem.020.202000224 · Cited by 24

Innovative strategies to advance CAR T cell therapy for solid tumors.

Huang, M., Jinniu, D., Gao, L., & Zhou, J. (2020) · PubMed Central · Cited by 24

Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers

Harrison, A. J., Du, X., von Scheidt, B., Kershaw, M. H., & Slaney, C. Y. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab016 · Cited by 24

Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)

Lu, J., Ding, J., Liu, Z., & Chen, T. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5302 · Cited by 24

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer

Yang, P., Fan, Y., Yao, Z., Xu, D., Xu, H., & Zhang, J. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03491-7 · Cited by 24

Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer

Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Military Medical Research · doi:10.1186/s40779-023-00486-4 · Cited by 24

Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series

Kambhampati, S., Gray, L., Fakhri, B., Lo, M., Vu, K., Arora, S., Kaplan, L., Ai, W. Z., & Andreadis, C. B. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.014 · Cited by 24

Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses

Fan, Y., Duan, Y., Chen, J., Wang, Y., Shang, K., Jiang, J., Su, L., Zhou, C., Sadelain, M., Huang, H., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01450-4 · Cited by 23

Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology

Yoo, H. J., & Harapan, B. N. (2021) · Immunologic Research · doi:10.1007/s12026-021-09236-x · Cited by 25

Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment

Jiang, L., Yao, Q., Yang, L., Miao, Y., Ren, W., Liu, H., Huang, Y., HUANG, S. H., Chen, S., Shi, Y., et al. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100852 · Cited by 23

Enhanced cellular therapy: revolutionizing adoptive cellular therapy

Xu, M., Zeng, N., Liu, C., Sun, J., An, Y., Zhang, S.-H., Xu, J., Zhong, X., Ma, S., He, H., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00506-6 · Cited by 24

Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

Houssaini, A. S., Lamrabet, S., Nshizirungu, J. P., Senhaji, N., Sekal, M., Karkouri, M., & Bennis, S. (2024) · Vaccines · doi:10.3390/vaccines12060655 · Cited by 24

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology

Choe, J. H., Williams, J. Z., & Lim, W. A. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033657 · Cited by 23

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance

Füchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 24

Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction

Krebs, S. S., Ponomarev, V., Slovin, S. F., & Schöder, H. M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227561 · Cited by 22

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics

Roussel, X., Daguindau, É., Berceanu, A., Desbrosses, Y., Warda, W., Rocha, M. N. D., Trad, R., Deconinck, É., Deschamps, M., & Ferrand, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599933 · Cited by 24

Designed improvement to T-cell immunotherapy by multidimensional single cell profiling

Bandey, I. N., Adolacion, J. R. T., Romain, G., Martinez-Paniagua, M. A., An, X., Saeedi, A., Liadi, I., You, Z., Rajanayake, R. B., Hwu, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001877 · Cited by 22

Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review

Kim, T. J., Lee, Y. H., & Koo, K. C. (2022) · Korean journal of urology · doi:10.4111/icu.20220103 · Cited by 22

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

Miao, L., Zhang, J., Xu, W., Qian, Q., Zhang, G., Yuan, Q., Lv, Y., Zhang, H., Shen, C., & Wang, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2338984 · Cited by 22

Chimeric antigen receptors: unleashing a new age of anti-cancer therapy

Leyfman, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0685-x · Cited by 24

Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology

Curran, M., Mairesse, M., Matas‐Céspedes, A., Bareham, B. R., Pellegrini, G., Liaunardy, A., Powell, E., Sargeant, R., Cuomo, E. M., Stebbings, R., et al. (2019) · Toxicologic Pathology · doi:10.1177/0192623319886304 · Cited by 23

TREM1/Dap12-based CAR-T cells show potent antitumor activity

Chen, B., Zhou, M., Zhang, H., Wang, C., Hu, X., Wang, B., & Wang, E. (2019) · Immunotherapy · doi:10.2217/imt-2019-0017 · Cited by 22

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Falgàs, A., Lázaro‐Gorines, R., Zanetti, S. R., Rubio-Pérez, L., Martínez-Moreno, A., Vinyoles, M., Guerrero-Murillo, M., Fernández‐Fuentes, N., Roca-Ho, H., Tirado, N., et al. (2025) · Blood · doi:10.1182/blood.2024025440 · Cited by 21

Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy

Zhang, A., Sun, Y., Wang, S., Du, J., Gao, X., Yuan, Y., Zhao, L., Yang, Y., Xu, L., Lei, Y., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.05.007 · Cited by 21

The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies

Zhylko, A., Winiarska, M., & Graczyk‐Jarzynka, A. (2020) · Cancers · doi:10.3390/cancers12082030 · Cited by 21

Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency

Duan, Y., Chen, J., Meng, X., Liu, L., Shang, K., Wu, X., Wang, Y., Huang, Z., Liu, H., Huang, Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.018 · Cited by 21

Universal CAR 2.0 to overcome current limitations in CAR therapy

Schlegel, L. S., Werbrouck, C., Boettcher, M., & Schlegel, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383894 · Cited by 21

CAR-T in solid tumors: Blazing a new trail through the brambles

Guo, F., & Cui, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118300 · Cited by 21

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy

Zhu, Y., Qian, Y., Li, Z., Li, Y., & Li, B. (2021) · MedComm · doi:10.1002/mco2.41 · Cited by 23

Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment

Yang, D. D., Macmorland, W., & Arnold, J. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643941 · Cited by 22

Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience

Metzinger, M. N., Verghese, C., Hamouda, D., Lenhard, A., Choucair, K., Senzer, N. N., Brunicardi, F. C., Dworkin, L. D., & Nemunaitis, J. J. (2019) · Oncology · doi:10.1159/000500488 · Cited by 20

The role of small molecules in cell and gene therapy

Brayshaw, L. L., Martinez-Fleites, C., Athanasopoulos, T., Southgate, T. D., Jespers, L. S., & Herring, C. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00221f · Cited by 21

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

Chen, K., Wang, S., Qi, D., Ma, P., Fang, Y., Jiang, N., Wu, E., & Li, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896685 · Cited by 22

Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy

Ghaderi, S. S., Riazi‐Rad, F., Qamsari, E. S., Bagheri, S., Jamnani, F. R., & Sharifzadeh, Z. (2022) · BMC Biotechnology · doi:10.1186/s12896-022-00752-8 · Cited by 21

CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma

Palaz, F., Özsöz, M., Zarrinpar, A., & Şahin, İ. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s456683 · Cited by 21

Updates on CAR T cell therapy in multiple myeloma

Nasiri, F., Asaadi, Y., Mirzadeh, F., Abdolahi, S., Molaei, S., Piri‐Gavgani, S., & Rahbarizadeh, F. (2024) · Biomarker Research · doi:10.1186/s40364-024-00634-5 · Cited by 20

Synergistic combination of oncolytic virotherapy with CAR T-cell therapy

Ajina, A., & Maher, J. F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.015 · Cited by 20

Overhauling CAR T Cells to Improve Efficacy, Safety and Cost

Chicaybam, L., Bonamino, M., Invitti, A. L., Rozenchan, P. B., Vieira, I. D. L., & Strauss, B. E. (2020) · Cancers · doi:10.3390/cancers12092360 · Cited by 20

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors

Schepisi, G., Conteduca, V., Casadei, C., Gurioli, G., Rossi, L., Gallá, V., Cursano, M. C., Brighi, N., Lolli, C., Menna, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.565857 · Cited by 20

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies

Lin, W., Wang, H., Chen, Y., Lin, C., Fan, H., & Lee, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228655 · Cited by 20

Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection

Peraro, L., Bourne, C. M., Dacek, M. M., Akalin, E., Park, J. H., Smith, E. L., & Scheinberg, D. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.022 · Cited by 20

Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours

Mao, R., Hussein, M. S., & He, Y. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.32 · Cited by 21

Dual-binding nanoparticles improve the killing effect of T cells on solid tumor

Luo, Z., Luo, L., Lu, Y., Zhu, C., Qin, B., Jiang, M., Li, X., Shi, Y., Zhang, J., Liu, Y., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01480-z · Cited by 20

Immunotherapy for Cholangiocarcinoma: a 2021 Update

Charalampakis, N., Papageorgiou, G., Tsakatikas, S. A., Fioretzaki, R., Kole, C., Kykalos, S., Tolia, M., & Schizas, D. (2021) · Immunotherapy · doi:10.2217/imt-2021-0126 · Cited by 19

Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)

Cassioli, C., Patrussi, L., Valitutti, S., & Baldari, C. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214255 · Cited by 20

Multiplexed engineering and precision gene editing in cellular immunotherapy

Biederstädt, A., Manzar, G. S., & Daher, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063303 · Cited by 19

Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env+ cells in vivo

Pan, H., Yang, X., Wang, J., Liang, H., Jiang, Z., Zhao, L., Wang, Y., Liang, Z., Shen, X., Lin, Q., et al. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.01.003 · Cited by 19

CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy

Sacchetti, B., Botticelli, A., Pierelli, L., Nuti, M., & Alimandi, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081903 · Cited by 19

Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells

Fang, Y., Zhang, Y., Guo, C., Chen, C., Gao, H., Zhou, X., Liu, T., & Qian, Q. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.008 · Cited by 21

How Can We Engineer CAR T Cells to Overcome Resistance?

Glover, M., Avraamides, S., & Maher, J. F. (2021) · Biologics · doi:10.2147/btt.s252568 · Cited by 19

CAR-T Cells Targeting Immune Checkpoint Pathway Players

Golubovskaya, V. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704121 · Cited by 19

Application of CAR T cells for the treatment of solid tumors

Khan, J. F., Khan, A. S., & Brentjens, R. J. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.004 · Cited by 19

Progress in the development of cytokine armoured CAR T cells

Prasad, K., Cross, R. S., & Jenkins, M. R. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01280-8 · Cited by 18

TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma

Wang, Q., Zheng, K., Tan, D., & Liang, G. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.10.079 · Cited by 18

Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition

Yuti, P., Wutti‐in, Y., Sawasdee, N., Kongkhla, K., Phanthaphol, N., Choomee, K., Chieochansin, T., Panya, A., Junking, M., Yenchitsomanus, P., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109442 · Cited by 19

Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment

Sadowski, K. A., Olejarz, W., & Basak, G. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315006 · Cited by 19

Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer

Polten, R., Kutle, I., Hachenberg, J., Klapdor, R., Morgan, M. A., & Schambach, A. (2022) · Cancers · doi:10.3390/cancers15010263 · Cited by 18

CAR-T cells for cancer immunotherapy

Xie, Y., Li, X., Wu, J., Zeng, H., Boucetta, H., Wang, B., Yang, P., & He, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108202 · Cited by 18

Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy

Mulgaonkar, A., Udayakumar, D., Yang, Y., Harris, S. F., Öz, O. K., Geethakumari, P. R., & Sun, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1199146 · Cited by 18

Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells

Stefanidis, E., Semilietof, A., Pujol, J., Seijo, B., Scholten, K. B. J., Zoete, V., Michielin, O. A., Sandaltzopoulos, R., Coukos, G., & Irving, M. B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci161660 · Cited by 18

T-cell receptor gene-modified cells: past promises, present methodologies and future challenges

Rego, R. T., Morris, E. C., & Lowdell, M. W. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.12.002 · Cited by 23

New targets and technologies for CAR-T cells

Freitag, F., Maucher, M., Riester, Z., & Hudecek, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000653 · Cited by 20

The Role of Immune Checkpoints after Cellular Therapy

Schmitz, F., Wolf, D. G. F., & Holderried, T. A. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103650 · Cited by 18

How to kill Treg cells for immunotherapy

Ellis, G. I., & Riley, J. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-00155-8 · Cited by 18

Long Noncoding RNA lncNDEPD1 Regulates PD-1 Expression via miR-3619-5p in CD8+ T Cells

Cheng, S., Li, F., Qin, H., Ping, Y., Zhao, Q., Gao, Q., Song, M., Qu, J., Shan, J., Zhang, K., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100602 · Cited by 17

Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model

Vitale, M., Scialò, F., Passariello, M., Leggiero, E., D'Agostino, A. G., Tripodi, L., Gentile, L., Bianco, A., Castaldo, G., Cerullo, V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.902190 · Cited by 17

Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer

Shen, Y., Liu, G., Zhang, Q., Tian, X., Ouyang, L., & Zhang, L. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.01.011 · Cited by 17

Abstract 2568: CAR T cells secreting an immune checkpoint blockade scFv have enhanced anti-tumor efficacy

Rafiq, S., Yeku, O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Yan, S., Wang, P., Xiang, J., Liu, C., Seshan, V., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2568

Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade

Rafiq, S., Jackson, H. J., Yeku, O., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Ahmed, R. N., Cullen, G. D., Yan, S., Wang, P., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.842.842 · Cited by 6

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv

Yü, P., Li, F., Nan, S., Zhang, D., Shi, X., Shan, J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00803 · Cited by 51

PD-1–Blocking scFV–Secreting CAR T Cells Exhibit Antitumor Efficacy

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-143

Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells

Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H., & Tamada, K. (2019) · Cancer Science · doi:10.1111/cas.14169 · Cited by 53